Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance, with a 46% YoY revenue increase, and strategic growth in VEVYE and IHEEZO. Despite risks in FDA approvals and market competition, the company shows robust market access and prescription growth. The lack of a share buyback program is a minor negative, but the overall sentiment is positive due to strong financial metrics and optimistic guidance for 2024.
Quarterly Revenue $48.9 million, a 46% increase year-over-year and a 42% increase quarter-over-quarter. This growth was attributed to contributions from every part of the business, particularly the Anterior Segment business and the ImprimisRx compounding subsidiary.
Branded Revenue vs Compounded Revenue Branded revenue is now ahead of compounded revenue, positively impacting margins. This shift indicates a strategic focus on branded products, which is expected to continue.
VEVYE Prescriptions Total prescriptions for VEVYE increased by 212% from the first quarter of 2024, driven by new prescriptions and a strong refill rate.
Market Access for VEVYE Covered lives for VEVYE now exceed 166 million, with commercial coverage at approximately 58% and Medicaid coverage at 80%, expected to reach 100% by the next quarter.
Territory Coverage for VEVYE Currently covering 36 out of 59 planned territories, with plans to expand salesforce and open new territories based on strong demand.
VEVYE prescriptions: Total prescriptions in the second quarter of 2024 increased 212% from the first quarter of this year.
TRIESENCE relaunch: Progress is being made towards the relaunch of TRIESENCE, with initial analytical testing of the second PPQ batch being in specification.
Market access for VEVYE: Covered lives now exceed 166 million, with commercial coverage at approximately 58% and Medicaid coverage at 80%, expected to reach 100% by the third quarter.
Supply agreements for IHEEZO: Signed 24 supply agreements with strategic retina practice accounts this year, including 10 in Q2.
Record quarterly revenue: Achieved record quarterly revenue of $48.9 million, a 46% increase over the prior year quarter.
Branded vs Compounded Revenue: Branded revenue is now firmly ahead of compounded revenue, positively impacting margins.
Expansion of VEVYE salesforce: Investing in expanding the VEVYE salesforce and opening new territories, currently covering 36 out of 59 markets.
Focus on revenue growth: Expect revenue in the back half of 2024 to outpace the first half, with a projected total revenue greater than $180 million.
FDA Approval Risks: Risks related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies, as well as the timely approval of certain drug candidates.
Market Competition: Competitive pressures in the ophthalmic pharmaceutical market, particularly with the introduction of new products and the need to maintain market access.
Supply Chain Challenges: Potential challenges in the supply chain that could affect the production and distribution of products, particularly with the relaunch of TRIESENCE.
Economic Factors: Economic uncertainties that could impact revenue projections and overall business performance.
Regulatory Issues: Ongoing regulatory scrutiny and compliance requirements that could affect operational capabilities and market entry.
Record Quarterly Revenue: Harrow achieved record quarterly revenue of $48.9 million, a 46% increase over the prior year quarter and a 42% increase over the previous quarter.
Branded Revenue Growth: Branded revenue is now firmly ahead of compounded revenue, contributing to higher margins.
Strategic Agreements: Signed 24 supply agreements with strategic retina practice accounts this year, including a significant agreement with the largest retina practice group in the U.S.
VEVYE Market Access Strategy: VEVYE is exceeding internal market access goals with covered lives beyond 166 million, commercial coverage at approximately 58%, and Medicaid coverage expected to reach 100%.
Expansion of VEVYE Salesforce: Harrow is investing in expanding the VEVYE salesforce and opening new territories.
2024 Revenue Expectations: Harrow expects 2024 revenue to be greater than $180 million, excluding any contribution from TRIESENCE.
Back Half of 2024 Revenue Growth: Revenue in the back half of 2024 is expected to outpace revenue in the first half of the year.
VEVYE Long-term Potential: Harrow intends to sell more VEVYE in 2035 than in 2025, indicating a long-term growth strategy.
Share Buyback Program: Harrow has not announced any share buyback program during the call.
The earnings call summary and Q&A highlight strong product development and market strategy, especially with VEVYE's market penetration and new PBM coverage. Although there are concerns regarding ASP decline and inventory shortages, the overall sentiment is positive due to expected revenue growth, strategic expansions, and leverage on SG&A. The positive guidance and strategic market moves outweigh the potential risks, leading to a likely positive stock price movement.
The earnings call summary indicates strong growth in key revenue segments like IHEEZO and TRIESENCE, with positive guidance for the future. Despite a decline in VEVYE revenue, prescription volumes are up, and ASPs are expected to rise. The Q&A section reveals management's confidence in growth strategies and upcoming launches, although some uncertainty remains around biosimilar timing. Overall, the positive growth outlook and strategic initiatives suggest a likely positive stock price movement.
The earnings call presents a strong financial performance with record revenue growth and optimistic future guidance. The Q&A section reinforces positive sentiment with strong demand for TRIESENCE and VEVYE, despite minor disruptions. The lack of share repurchase announcements and some regulatory risks are potential concerns, but the overall outlook with strategic agreements and market expansion is favorable. The absence of market cap data suggests a moderate impact on stock price, leading to a positive prediction.
The earnings call reveals strong financial performance, with a 46% YoY revenue increase, and strategic growth in VEVYE and IHEEZO. Despite risks in FDA approvals and market competition, the company shows robust market access and prescription growth. The lack of a share buyback program is a minor negative, but the overall sentiment is positive due to strong financial metrics and optimistic guidance for 2024.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
